Amicus Therapeutics Revenue Quarterly:
0.00 for Dec. 31, 2012Amicus Therapeutics Historical Revenue Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 0.00 |
| Sept. 30, 2012 | 0.00 |
| June 30, 2012 | 10.64M |
| March 31, 2012 | 7.774M |
| Dec. 31, 2011 | 5.63M |
| Sept. 30, 2011 | 5.798M |
| June 30, 2011 | 4.04M |
| March 31, 2011 | 5.966M |
| Dec. 31, 2010 | 0.922M |
| Sept. 30, 2010 | 0.00 |
| June 30, 2010 | 0.00 |
| March 31, 2010 | 0.00 |
| Dec. 31, 2009 | 49.48M |
| Sept. 30, 2009 | 4.913M |
| June 30, 2009 | 5.361M |
| March 31, 2009 | 4.606M |
| Dec. 31, 2008 | 4.345M |
| Sept. 30, 2008 | 3.653M |
| June 30, 2008 | 3.807M |
| March 31, 2008 | Go Pro |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity. Increasing revenues over time are generally a good sign of company's growth.
While a bit obvious, if a lemonade company has sold 30 million in revenue and has 10 million in costs of goods sold, the company's revenue is still 30 million. (Expenses are not accounted in Revenue).
Learn More
FOLD Revenue Quarterly Benchmarks
| Companies | |
|---|---|
| Durata Therapeutics | 0.00 |
| Zalicus | 3.674M |
| Insmed | 0.00 |
FOLD Revenue Quarterly Rankings
| Overall |
37th percentile 4982 of 8008 |
| Sector |
21st percentile 537 of 685 in Healthcare |
| Industry |
33rd percentile 165 of 249 in Biotechnology |
FOLD Revenue Quarterly Range, Past 5 Years
| Minimum | 0.00 | Mar 2010 |
| Maximum | 49.48M | Dec 2009 |
| Average | 6.154M |
